October 29, 2025 – CounterX Therapeutics

October 29, 2025 in Press Release

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

PRESS RELEASE CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model SEA ...

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

Psychopharmacology: A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys

ACS Omega: Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

Expert Opinion Investigational Drugs: The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model